Morning Trend | LUYE PHARMA retraces to the stage low, can sector linkage change the weakness?
Luye Pharma (2186.HK) has recently seen its stock price continue to decline, temporarily retracing to the previous low point area. The daily death cross signal is clear, and the short-term bearish atmosphere dominates the market. From a technical perspective, major indicators such as MACD and RSI are showing weakness, with the 5-day and 10-day moving averages continuing to decline, and the K-line combination leaning bearish, indicating ongoing market selling pressure.
On the fundamental side, although Luye Pharma has launched some new drugs, the industry as a whole has entered a complex phase characterized by stricter policy regulation, price reductions in medical insurance, and high R&D expenditures, leading to many uncertainties affecting short-term performance improvement. The overall performance of the pharmaceutical sector has recently seen a decline in participation enthusiasm, with major institutions preferring defensive industries or rotating into high-growth areas.
In terms of sector linkage, the pharmaceutical sector is weak, with noticeable short-term capital outflows. Luye Pharma is constrained by the overall atmosphere, facing systemic adjustment pressure brought about by the industry's "collective bearish" sentiment. In the current sensitive range of the retracement phase, both institutions and short-term funds remain highly sensitive, with price fluctuations easily triggering sector resonance.
For future trends, attention should be paid to whether the support at this low point is effective. If strong support is breached, short-term bearish signals may further strengthen; conversely, if funds provide support and lead to a reversal of indicators, there may be a technical rebound in the short term. Investors should strictly control risks, primarily adopting a wait-and-see approach when the bottom is unclear, and if making tentative layouts, set appropriate stop-loss levels
Technical Forecast·
